The protein has a calculated MW of 6.3 kDa. The protein migrates as 6.3 kDa under reducing (R) condition (SDS-PAGE).
Less than 1.0 EU per μg by the LAL method.
>97% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Human EGF, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 97%.
Immobilized Human EGF, Tag Free (Cat. No. EGF-H4114) at 10 μg/mL (100 μL/well) can bind Biotinylated Human EGF R, His Tag, Avi Tag (Cat. No. EGR-H82E3) with a linear range of 0.156-5 μg/mL (QC tested).
Human epidermal growth factor (EGF) is also known as HOMG4 and URG,and is a growth factor that plays an important role in the regulation of cell growth, proliferation, and differentiation by binding to its receptor EGFR. Epidermal growth factor can be found in human platelets, macrophages, urine, saliva, milk, and plasma. EGF is the founding member of the EGF-family of proteins. Members of this protein family have highly similar structural and functional characteristics. All family members contain one or more repeats of the conserved amino acid sequence. The biological effects of salivary EGF include healing of oral and gastroesophageal ulcers, inhibition of gastric acid secretion, stimulation of DNA synthesis as well as mucosal protection from intraluminal injurious factors such as gastric acid, bile acids, pepsin, and trypsin and to physical, chemical and bacterial agents. Because of the increased risk of cancer by EGF, inhibiting it decreases cancer risk.